Advice
Following a full submission
levetiracetam (Keppra®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy.
In the pivotal study, levetiracetam reduced partial seizure frequency compared to placebo in both the treatment and evaluation phases.
The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC. The licence holder has indicated their decision to resubmit.
Download detailed advice90KB (PDF)
Medicine details
- Medicine name:
- levetiracetam 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra)
- SMC ID:
- 394/07
- Indication:
- Adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in children from 4 years of age with epilepsy
- Pharmaceutical company
- UCB Pharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Not recommended
- Date advice published
- 10 September 2007